US FDA proposals for naming of biologicals and labelling of biosimilars

Author:
  • GEGaBI Journal Editor
    GaBI Journal Editor

Abstract
There is considerable concern and debate over the naming of biologicals and labelling of biosimilars. To ensure that patients receive the safest and